NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 356 filers reported holding NEKTAR THERAPEUTICS in Q1 2019. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $46,565 | -85.9% | 20,604 | -76.3% | 0.00% | -75.0% |
Q2 2022 | $330,000 | -57.3% | 86,957 | -39.3% | 0.01% | -60.0% |
Q1 2022 | $773,000 | +273.4% | 143,364 | +835.2% | 0.03% | +233.3% |
Q4 2021 | $207,000 | -90.7% | 15,330 | -88.1% | 0.01% | -93.7% |
Q2 2021 | $2,215,000 | +282.6% | 129,105 | +346.3% | 0.14% | +389.7% |
Q1 2021 | $579,000 | -75.9% | 28,931 | -79.5% | 0.03% | -72.1% |
Q4 2020 | $2,404,000 | +321.0% | 141,395 | +311.1% | 0.10% | +285.2% |
Q3 2020 | $571,000 | +72.0% | 34,393 | +139.9% | 0.03% | +58.8% |
Q2 2020 | $332,000 | -52.4% | 14,339 | -63.3% | 0.02% | -66.0% |
Q1 2020 | $697,000 | +87.9% | 39,029 | +126.9% | 0.05% | +212.5% |
Q4 2019 | $371,000 | -85.3% | 17,200 | -87.5% | 0.02% | -87.5% |
Q3 2019 | $2,516,000 | +425.3% | 138,142 | +924.9% | 0.13% | +392.3% |
Q2 2019 | $479,000 | -15.8% | 13,478 | -20.4% | 0.03% | -23.5% |
Q1 2019 | $569,000 | -3.1% | 16,940 | -60.3% | 0.03% | -26.1% |
Q1 2016 | $587,000 | +179.5% | 42,687 | +214.7% | 0.05% | -23.3% |
Q4 2014 | $210,000 | – | 13,563 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |